Last reviewed · How we verify
Aminobenzoate Potassium (aminobenzoic acid)
Aminobenzoate Potassium (generic name: aminobenzoic acid) is a Vitamin B Complex Member drug. It is currently in unknown development for Dermatomyositis, Induratio penis plastica, Morphea.
Aminobenzoate Potassium works by inhibiting the enzyme carbonic anhydrase 2, which plays a crucial role in maintaining the pH balance in cells.
Aminobenzoate Potassium is a small molecule. It has been studied in clinical trials for various conditions, including Dry Socket, HIV Infections, Osteomyelitis, Obesity, and Heart Failure.
At a glance
| Generic name | aminobenzoic acid |
|---|---|
| Drug class | Vitamin B Complex Member |
| Target | Carbonic anhydrase 2 |
| Therapeutic area | Dermatology |
| Phase | unknown |
Mechanism of action
Think of carbonic anhydrase 2 like a thermostat in your body. It helps keep the pH levels in your cells just right. When this enzyme gets out of balance, it can lead to various skin problems. Aminobenzoate Potassium helps restore balance by blocking the enzyme's activity, reducing inflammation and promoting healing.
Approved indications
- Dermatomyositis
- Induratio penis plastica
- Morphea
- Pemphigus
- Systemic sclerosis
Common side effects
- Appendicolith
- Somnolence
- Blood phosphorus increased
- Appendicitis
- Pneumonia aspiration
- Ventricular fibrillation
- Coma
- Blood uric acid increased
- Gastrooesophageal reflux disease
- Cardiogenic shock
Key clinical trials
- Comparison of 4 Methods of Eye Drops for Pupil Dilation in Diabetic Patients (NA)
- Restoration of Hypoglycemia Awareness With Metoclopramide (PHASE2)
- A Study Evaluating the Safety, Tolerability and Pharmacokinetics of ASY202 in Healthy Adults (PHASE1)
- Mechanisms Underlying Hypotensive Response to ARB/NEP Inhibition - Aim 3 (PHASE4)
- The Impact of Intrapleural Block on Postoperative Pain Caused by Drainage Tubes After Thoracoscopic Surgery (NA)
- NEPC Study: An Exploratory Safety and Efficacy Study With PSMA, SSTR2 and GRPR Targeted Radioligand Therapy in Metastatic Neuroendocrine Prostate Cancer. (PHASE1)
- Olanzapine Plus Metoclopramide for the Prevention of Opioid-Induced Nausea and Vomiting (PHASE3)
- Comparative Study of Two Topical Anesthetics Prior to Fractional Nonablative Laser Treatment of the Face (PHASE2,PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Aminobenzoate Potassium CI brief — competitive landscape report
- Aminobenzoate Potassium updates RSS · CI watch RSS
- portfolio CI
Frequently asked questions about Aminobenzoate Potassium
What is Aminobenzoate Potassium?
How does Aminobenzoate Potassium work?
What is Aminobenzoate Potassium used for?
What is the generic name of Aminobenzoate Potassium?
What drug class is Aminobenzoate Potassium in?
What development phase is Aminobenzoate Potassium in?
What are the side effects of Aminobenzoate Potassium?
What does Aminobenzoate Potassium target?
Related
- Drug class: All Vitamin B Complex Member drugs
- Target: All drugs targeting Carbonic anhydrase 2
- Manufacturer: — full pipeline
- Therapeutic area: All drugs in Dermatology
- Indication: Drugs for Dermatomyositis
- Indication: Drugs for Induratio penis plastica
- Indication: Drugs for Morphea
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing